The Alpha-1 Project (TAP)

The Alpha-1 Project (TAP) is a funding program that supports new drug discovery and development in Alpha-1 by investing in pharmaceutical and biotech companies working to eradicate the effects of liver disease and COPD caused by Alpha-1. 

TAP funding helps bridge the gap between academic research and the development of new drug targets and devices, and supports promising advancements through clinical trials and into commercialization.

To date, TAP has invested in 12 therapies directly targeting Alpha-1—five of which are in active clinical trials—and four tools that assist in the therapeutic development process.

For more information, please contact Randel Plant at or 1-877-228-7321, ext. 306